Novel Pathways in Ischemic Stroke in Sickle Cell Anemia
镰状细胞贫血症缺血性中风的新途径
基本信息
- 批准号:10200126
- 负责人:
- 金额:$ 51.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdhesionsAffectAllelesAnimal ModelBiochemicalBiologicalBiological AssayBiomimeticsBlood PlateletsBlood TransfusionCandidate Disease GeneCaringCell LineChronicClinicalCodeComplexComplicationDataDevelopmentDiphosphatesDiseaseEndothelial CellsEndotheliumEnzymesExpression ProfilingFunctional disorderFundingGenesGeneticGenetic TranscriptionGoalsGolgi ApparatusHeritabilityHydrolysisIn VitroInflammatoryInjuryInsulin ReceptorInterventionIschemic StrokeKineticsLinkLipidsLiquid substanceMaintenanceMeasuresMediatingMediator of activation proteinMicrofluidicsMissense MutationModelingModificationMolecularMutationOutputPathogenesisPathway interactionsPatientsPediatric HospitalsPhysiologicalPlasmaProcessPrognosisProtein Activation PathwayProtein SecretionProteinsProteomicsPublic HealthReceptor SignalingRecurrenceReportingResearchResourcesRiskRoleSamplingSickle Cell AnemiaSignal TransductionSorting - Cell MovementStenosisStrokeStroke preventionStructural ProteinStructureSystemTestingTexasThrombosisThrombusVariantVascular DiseasesVascular Endotheliumcalcificationcerebrovascularcohortexome sequencinggenetic variantgenome wide association studyhigh resolution imaginghydroxyureaimprovedmonocytenovelnovel therapeuticspediatric patientsprotein expressionprotein transportresponseshear stressstroke riskstroke therapytargeted treatmenttheoriesthromboticvon Willebrand Factor
项目摘要
Stroke is a devastating complication of sickle cell anemia (SCA) that will occur in ~11% of all patients without
intervention. In pediatric patients with SCA, most of these strokes are ischemic and strongly linked with arterial
vasculopathy. There is a strong heritable component that affects development of stroke in SCA patients.
However, our understanding of the genes involved is very limited. Our group reported an unbiased genome wide
association study of stroke in SCA using whole exome sequencing. We identified and validated two particular
missense mutations in the GOLGB1 (Y1212C) and ENPP1 (K173Q) genes as being protective against stroke in
SCA. Our study goal is to define the functional role of GOLGB1 and ENPP1 as modulators of vascular endothelial
injury and ischemic stroke risk.
We have previously observed that: a) GOLGB1 levels affect Golgi structure in monocytes and endothelial
cells; b) The GOLGB1 Y1212C variant is associated with more dispersed Golgi in monocytes isolated from SCA
patients; and c) ENPP1 enzymatic activity is higher in SCA patients with the protective K allele of the ENPP1
K173Q variant. From this preliminary data, we hypothesize that 1) GOLGB1 affects Golgi structure, which in turn
regulates secretory output of pro-thrombotic factors such as von Willebrand factor (vWF) that can affect stroke
in SCA; and 2) that ENPP1 affects risk of thrombosis either through endothelial cell signaling or by hydrolysis of
the pro-inflammatory ATP inorganic pyrophosphate (PPi). We plan to test these hypotheses by analyzing the
function of GOLGB1 and ENPP1 in samples from patients with SCA. We will isolate primary monocyte and
endothelial cells from a large cohort of SCA patients receiving care at Texas Children’s Hospital.We will test our
central hypotheses by pursuing three aims: Aim 1: Examine the role of GOLGB1 in the structure and function of
Golgi complexes in sickle cell anemia - We will use high resolution imaging to determine the role of GOLGB1 in
maintaining Golgi structure and protein trafficking in monocyte and endothelial cells from SCA patients; Aim 2:
Determine the effect of ENPP1 activity in sickle cell anemia - We will measure plasma and endothelial activity of
the ENPP1 enzyme.We will also test whether ENPP1 modulates vascular dysfunction in patients with SCA; Aim
3: Determine impact of GOLGB1 and ENPP1 on endothelial activation in a microfluidic arterial model - We will
combine thrombotic protein assays and RNA expression profiling to identify endothelial activation pathways
affected by our candidate genes.
Our proposed studies will characterize the functional impact of our two genes and their genetic variants
in SCA patient samples. This will benefit our understanding of the pathophysiological pathways of stroke and
potentially provide targets for drug therapy to prevent or treat stroke in SCA patients.
卒中是镰状细胞性贫血(SCA)的一种毁灭性并发症,约11%的患者会发生卒中,
干预在患有SCA的儿科患者中,大多数卒中是缺血性的,与动脉粥样硬化密切相关。
血管病变有一个很强的遗传成分,影响中风的发展,在SCA患者。
然而,我们对相关基因的了解非常有限。我们的小组报告了一个无偏见的全基因组
使用全外显子组测序进行SCA中卒中的关联研究。我们确定并验证了两个特定的
GOLGB 1(Y1212 C)和ENPP 1(K173 Q)基因的错义突变对中风有保护作用,
SCA。我们的研究目标是确定GOLGB 1和ENPP 1作为血管内皮细胞生长因子的调节剂的功能作用。
损伤和缺血性中风风险。
我们以前观察到:a)GOLGB 1水平影响单核细胞和内皮细胞中的高尔基体结构,
B)GOLGB 1 Y1212 C变体与分离自SCA的单核细胞中更分散的高尔基体相关
c)在具有ENPP 1的保护性K等位基因的SCA患者中,ENPP 1酶活性更高
K173 Q变种。根据这些初步数据,我们假设1)GOLGB 1影响高尔基体结构,进而影响高尔基体结构,
调节促血栓形成因子如血管性血友病因子(vWF)的分泌,
在SCA中;和2)ENPP 1通过内皮细胞信号传导或通过
促炎性ATP无机焦磷酸盐(PPi)。我们计划通过分析这些假设来验证这些假设。
在来自SCA患者的样品中GOLGB 1和ENPP 1的功能。我们将分离初级单核细胞,
内皮细胞从一个大队列的SCA患者接受照顾在得克萨斯州儿童医院。我们将测试我们的
通过追求三个目标的中心假设:目标1:检查GOLGB 1在结构和功能中的作用,
镰状细胞性贫血中的高尔基复合体-我们将使用高分辨率成像来确定GOLGB 1在镰状细胞性贫血中的作用。
维持来自SCA患者的单核细胞和内皮细胞中的高尔基体结构和蛋白质运输;目的2:
确定ENPP 1活性在镰状细胞性贫血中的作用-我们将测量ENPP 1的血浆和内皮活性。
我们还将测试ENPP 1是否调节SCA患者的血管功能障碍;目的
3:确定GOLGB 1和ENPP 1对微流体动脉模型中内皮活化的影响-我们将
联合收割机和RNA表达谱分析鉴定内皮活化途径
受候选基因的影响
我们提出的研究将描述我们的两个基因及其遗传变异的功能影响
在SCA患者样本中。这将有助于我们理解中风的病理生理学途径,
潜在地为预防或治疗SCA患者的中风的药物治疗提供靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jonathan Michael Flanagan其他文献
Jonathan Michael Flanagan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jonathan Michael Flanagan', 18)}}的其他基金
NOVEL PATHWAYS IN ISCHEMIC STROKE IN SICKLE CELL ANEMIA
镰状细胞性贫血缺血性中风的新途径
- 批准号:
9565807 - 财政年份:2017
- 资助金额:
$ 51.6万 - 项目类别:
相似海外基金
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y004841/1 - 财政年份:2024
- 资助金额:
$ 51.6万 - 项目类别:
Research Grant
Defining a role for non-canonical mTORC1 activity at focal adhesions
定义非典型 mTORC1 活性在粘着斑中的作用
- 批准号:
BB/Y001427/1 - 财政年份:2024
- 资助金额:
$ 51.6万 - 项目类别:
Research Grant
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y005414/1 - 财政年份:2024
- 资助金额:
$ 51.6万 - 项目类别:
Research Grant
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
- 批准号:
10669829 - 财政年份:2023
- 资助金额:
$ 51.6万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10587090 - 财政年份:2023
- 资助金额:
$ 51.6万 - 项目类别:
Improving Maternal Outcomes of Cesarean Delivery with the Prevention of Postoperative Adhesions
通过预防术后粘连改善剖宫产的产妇结局
- 批准号:
10821599 - 财政年份:2023
- 资助金额:
$ 51.6万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10841832 - 财政年份:2023
- 资助金额:
$ 51.6万 - 项目类别:
Prevention of Intraabdominal Adhesions via Release of Novel Anti-Inflammatory from Surface Eroding Polymer Solid Barrier
通过从表面侵蚀聚合物固体屏障中释放新型抗炎剂来预防腹内粘连
- 批准号:
10532480 - 财政年份:2022
- 资助金额:
$ 51.6万 - 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
- 批准号:
10741261 - 财政年份:2022
- 资助金额:
$ 51.6万 - 项目类别:
Sprayable Polymer Blends for Prevention of Site Specific Surgical Adhesions
用于预防特定部位手术粘连的可喷涂聚合物共混物
- 批准号:
10674894 - 财政年份:2022
- 资助金额:
$ 51.6万 - 项目类别:














{{item.name}}会员




